Free provider profile
ALI MOUSSA, M.D.
Need more providers like ALI MOUSSA?
See the count and top 3 free, ranked by Medicare billing. Full list $29, included with membership.
Rep intel
What ALI MOUSSA prescribes and who else does
Top Medicare Part D drugs by claims (public CMS data):
- Imbruvica
- Revlimid
- Calquence
- Cabometyx
- Venclexta
Your next referral list starts here
Provider + market indicator
A combined screening indicator—not a provider fraud-risk score. Local plan ratings describe the surrounding market, not this provider’s quality, plan membership or wrongdoing.
Comparing current CMS billing with peers and checking OIG and plan ratings… A new peer comparison can take about a minute.
Practice contact card
Practice phone
918-505-3200
Fax
918-505-3253
Practice address
12697 E 51ST ST, TULSA, OK, 74146
- Registry updated
- 2020-09-02
- NPI issued
- 2006-06-02
- RepVector retrieved
- 11/20/2026
A recent retrieval can still contain an old address if the provider has not updated their registry record. Website email checks show their own date under Find email.
Registry record
Source: CMS NPPES registry.
12697 E 51ST ST, TULSA, OK, 74146
918-505-3200
Single practice location
Enumerated 2006-06-02
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — Record last updated 6 years ago.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
4,171
Medicare patients
578
Part D drug cost
$7,163,554
Brand-name share
Not published
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Cabometyx (Cabozantinib S-Malate) | 42 | $1,079,912 |
| Imbruvica (Ibrutinib) | 51 | $810,517 |
| Revlimid (Lenalidomide) | 48 | $740,764 |
| Calquence (Acalabrutinib Maleate) | 43 | $520,004 |
| Brukinsa (Zanubrutinib) | 30 | $412,815 |
| Tagrisso (Osimertinib Mesylate) | 26 | $404,218 |
| Venclexta (Venetoclax) | 32 | $366,619 |
| Ibrance (Palbociclib) | 24 | $361,407 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Latest Medicare Part B billing
CMS Physician and Other Practitioners, by Provider and Service. New published billing years are detected daily, using the same release as the Billing analyst and risk maps.
Loading the latest published CMS billing file…
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
Checking Open Payments…
Industry payments across OK — which companies pay providers there.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.
